Nippon Kayaku
4272.TTSE PRIMEChemicals
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥241.9bn | ¥222.6bn | ¥201.8bn | ¥198.4bn | ¥184.8bn | ¥173.4bn |
| Operating income | ¥22.5bn | ¥20.4bn | ¥7.3bn | ¥21.5bn | ¥21.1bn | ¥15.2bn |
| Ordinary income | ¥25.5bn | ¥22.3bn | ¥12.6bn | ¥23.0bn | ¥23.2bn | ¥16.5bn |
| Net income (owners) | ¥24.6bn | ¥17.5bn | ¥4.1bn | ¥15.0bn | ¥17.2bn | ¥12.6bn |
| Total assets | ¥398.7bn | ¥373.7bn | ¥363.2bn | ¥322.9bn | ¥315.5bn | ¥294.5bn |
| Net assets / equity | ¥280.1bn | ¥268.5bn | ¥270.5bn | ¥255.0bn | ¥246.4bn | ¥228.3bn |
| Operating cash flow | ¥28.8bn | ¥25.5bn | ¥23.2bn | ¥20.0bn | ¥23.1bn | ¥24.4bn |
| EPS (basic) | ¥161.18 | ¥107.17 | ¥24.8 | ¥89.36 | ¥101.7 | ¥73.62 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 207 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 74 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 207 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 74 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 207 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 52 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 76 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 50 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 208 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 52 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 76 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 50 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 208 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Fine Chemicals Business Unit | ¥74.1bn | ¥11.9bn |
| Life Science Business Unit | ¥73.0bn | ¥9.7bn |
| Mobility And Imaging Business Unit | ¥94.7bn | ¥10.7bn |
| Adjustments & eliminations | — | −¥9.8bn |
| Total | ¥241.9bn | ¥32.3bn |
| Total | ¥241.9bn | ¥32.3bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.